Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spot hidden tumors more accurately

NCT ID NCT03583528

Diagnosis Sponsor: British Columbia Cancer Agency Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new type of PET/CT scan, using a radioactive tracer called 68Ga-DOTATOC, can find neuroendocrine tumors (NETs) and similar tumors more safely and accurately than current imaging methods. About 800 people with known or suspected NETs will receive the scan, and researchers will compare results with standard imaging and pathology reports. The goal is to see if this scan can better detect tumors that have a high number of somatostatin receptors on their surface.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2018

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This will be a prospective, open-label trial in patients with suspected or proven SSTR positive tumors.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All subjects: * World health organization performance status 0-2 * Able to provide written informed consent/assent (or consent by guardian for subjects \<19 years) * Patients must be able to tolerate the physical/logistical requirements of completing a PET scan including lying flat for up to 30 minutes and tolerating intravenous cannulation for injection. Patients must require imaging for either staging or re-staging of: * Gastroenteropancreatic tumors (e.g. carcinoids, gastrinoma, insulinoma, glucagonoma, VIPoma, etc.), functioning and non-functioning * Sympathoadrenal system tumors (phaeochromocytoma, paraganglioma, neuroblastoma, ganglioneuroma) * Medullary thyroid carcinoma * Pituitary adenoma * Medulloblastoma * Merkel cell carcinoma * Small-cell lung cancer (mainly primary tumors) * Meningioma * Or any other NET / with potential for overexpression of SSTR Exclusion Criteria: * Pregnancy * Patients who are medically unstable ex: acute cardiac or respiratory distress, hypotensive * Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70cm).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoid tumor Carcinoma, Medullary cutaneous neuroendocrine carcinoma gangliocytoma ganglioneuroma gastrin-producing neuroendocrine tumor glucagonoma medullary thyroid gland carcinoma medulloblastoma meningioma neuroblastoma neuroendocrine neoplasm pancreatic gastrin-producing neuroendocrine tumor pancreatic insulinoma paraganglioma pheochromocytoma pituitary gland adenoma Pituitary Neoplasms small cell lung carcinoma VIPoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoid Ganglioneuroma Gastrinoma Glucagonoma Insulinoma Medullary carcinoma Medulloblastoma Meningioma Merkel cell carcinoma Neuroblastoma Neuroendocrine tumors Paraganglioma Pheochromocytoma Pituitary adenoma Small cell lung cancer VIPOMA

Contacts and locations

Locations

  • BC Cancer

    Vancouver, British Columbia, V5Z 4E6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.